Abstract

Large vessel vasculitis (LVV) is defined as a disease mainly affecting the large arteries, with two major variants, Takayasu arteritis (TA) and giant cell arteritis (GCA). GCA often coexists with polymyalgia rheumatica (PMR) in the same patient, since both belong to the same disease spectrum. FDG-PET/CT is a functional imaging technique which is an established tool in oncology, and has also demonstrated a role in the field of inflammatory diseases. Functional FDG-PET combined with anatomical CT angiography, FDG-PET/CT(A), may be of synergistic value for optimal diagnosis, monitoring of disease activity, and evaluating damage progression in LVV. There are currently no guidelines regarding PET imaging acquisition for LVV and PMR, even though standardization is of the utmost importance in order to facilitate clinical studies and for daily clinical practice. This work constitutes a joint procedural recommendation on FDG-PET/CT(A) imaging in large vessel vasculitis (LVV) and PMR from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine (EANM), the Cardiovascular Council of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), and the PET Interest Group (PIG), and endorsed by the American Society of Nuclear Cardiology (ASNC). The aim of this joint paper is to provide recommendations and statements, based on the available evidence in the literature and consensus of experts in the field, for patient preparation, and FDG-PET/CT(A) acquisition and interpretation for the diagnosis and follow-up of patients with suspected or diagnosed LVV and/or PMR. This position paper aims to set an internationally accepted standard for FDG-PET/CT(A) imaging and reporting of LVV and PMR.

Highlights

  • Large vessel vasculitis (LVV) is defined as a disease mainly affecting the large arteries, with two major variants, Takayasu arteritis (TA) and giant cell arteritis (GCA) [1]

  • The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and European Association of Nuclear Medicine (EANM) will periodically define new guidelines for nuclear medicine practice to help advance the science of nuclear medicine and to improve the quality of care to patients throughout the world

  • The paper highlights the importance of standardization and optimal procedural performance of FDG-positron emission tomography–computed tomography (PET/CT)(A) imaging in LVV and polymyalgia rheumatica (PMR), and emphasizes the importance of bridging the gap between imaging specialists and clinicians working in this field

Read more

Summary

Introduction

Large vessel vasculitis (LVV) is defined as a disease mainly affecting the large arteries, with two major variants, Takayasu arteritis (TA) and giant cell arteritis (GCA) [1]. FDG-PET is based on the ability to detect enhanced glucose uptake from high glycolytic activity of inflammatory cells in inflamed arterial walls and synovia/bursa [9] Thereby, it can identify the presence of systemic LVV in patients with GCA and TA, and it can show inflammation of peri-articular and extra-articular synovial structures in the case of PMR. There are currently no guidelines regarding PET imaging acquisition for LVV and PMR, even though standardization is of the utmost importance for facilitating clinical studies and for daily clinical practice The aim of this joint paper is to provide recommendations and statements, based on the available evidence in the literature and consensus of experts in the field, for patient preparation and FDG-PET/CT(A) acquisition and interpretation in the diagnosis and follow-up of patients with suspected or diagnosed LVV and/or PMR. Quantification issues requiring further clarification Several semiquantitative methods have been proposed, from simple SUV metrics to target-to-background ratios (TBR) (Table 2)

Conclusion
Findings
Compliance with ethical standards

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.